Drug intelligence / Profile preview

Debio 0931

Development stage: Preclinical
Lead developer: Debiopharm
Modality: Small Molecules

Overview

Debio 0931 (also known as IRC-083864) is a first-in-class small molecule inhibitor of the CDC25 phosphatase enzyme, which plays a critical role in regulating the cell cycle. Overexpression of CDC25 is frequently associated with cancer progression, making it a target for therapeutic intervention. By inhibiting this enzyme, Debio 0931 blocks cell cycle progression and interrupts tumor growth. The drug was originally developed by Ipsen and was licensed to Debiopharm Group in 2009 for worldwide development and commercialization, specifically for oncology applications.

Targets

CDC25 (CDC25 phosphatase family)

Beyond the preview

Go deeper on Debio 0931.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Debio 0931.

Explore the full profile